HIV-1 Strain and Primary Drug Resistance in Canada
Surveillance Report to June 30, 2002

PDF Version (5814 KB)

December 2002

Division of HIV/AIDS Epidemiology and Surveillance
National HIV and Retrovirology Laboratories
Centre for Infectious Disease Prevention and Control
Public Health Agency of Canada
Health Canada

---

Table of Contents

Information to the readers of HIV-1 Strain and Primary Drug Resistance in Canada

Canadian HIV Strain and Drug Resistance Program
Contact Information – Health Canada

Canadian HIV Strain and Drug Resistance Surveillance Program
Contact Information – Provincial Partners

Results at a Glance

Introduction 

• An Overview of the Canadian HIV Strain and Drug Resistance Surveillance Program
• Goals of the CHSDRSP 

Methodology

• Epidemiologic data and laboratory specimen collection and transfer
• Genetic algorithm for HIV subtyping and drug resistance testing
• Consensus of major mutations associated with primary drug resistance
• Epidemiologic analyses

HIV-1 Primary Drug Resistance (1997-2001)

• Background
• Laboratory tests to detect drug resistance
• Data sources
• Prevalence and determinants of HIV-1 primary drug resistance in the sample population (N = 847)

Table 1
Prevalence of primary drug resistance among treatment naive individuals with newly diagnosed infection (1997-2001)

Table 2
Major mutations identified in HIV-1 reverse transcriptase and protease

Table 3
Prevalence of drug resistance among treatment naive individuals with newly diagnosed infection by year of diagnosis 

Table 4
Prevalence of drug resistance among treatment naive individuals with newly diagnosed infection by province

Table 5
Prevalence of drug resistance among treatment naive individuals with newly diagnosed infection by age at diagnosis

Table 6
Prevalence of drug resistance among treatment naive individuals with newly diagnosed infection by gender

Table 7
Prevalence of drug resistance among treatment naive individuals with newly diagnosed infection by exposure category 

Table 8
Prevalence of drug resistance among treatment naive individuals with newly diagnosed infection by ethnicity 

Table 9
Prevalence of drug resistance among treatment naive individuals by HIV-1 subtype

Table 10
Prevalence of drug resistance among treatment naive individuals by recently acquired versus prevalent HIV-1 infection

Table 11
Summary of key studies on drug resistance among treatment naive individuals with newly diagnosed infection in Canada

Table 12
Summary of key studies on drug resistance among treatment naïve individuals with newly diagnosed infection in the United States and in Western Europe

HIV-1 Subtypes (1984-January 2002)

• Background 
• Data sources
• Prevalence of HIV-1 subtypes among treatment naive individuals with newly diagnosed infection 
  

Table 13
Prevalence of HIV-1 subtypes among treatment naive individuals with newly diagnosed infection

Table 14
Prevalence of HIV-1 subtypes by year of diagnosis with HIV-1 infection

Table 15
Prevalence of HIV-1 subtypes by province

Table16
Prevalence of HIV-1 subtypes by age of diagnosis with HIV-1 infection

Table 17
Prevalence of HIV-1 subtypes by gender

Table 18
Prevalence of HIV-1 subtypes by exposure category

Table 19
Prevalence of HIV-1 subtypes by ethnicity

Table 20
Prevalence of HIV-1 subtypes by recently acquired versus prevalent HIV-1 infections

Table 21
Prevalence of HIV-1 subtypes by primary drug resistance

Table 22
Epidemiologic characteristics of individuals infected with non-B subtypes of HIV-1

National HIV Reference Services 

• Background
• Table 23
  HIV-1 subtype distribution of samples submitted to reference services
• HIV-2 infections

Technical Notes

Data Limitations 

Appendix 1. Glossary of terms

Appendix 2. List of primary mutations

[Table of Contents] [Next]